China Healthcare Stocks On Recovery Path After $142 Billion Rout
Chinese healthcare stocks are back in vogue after a $142 billion wipeout, as signs grow that the worst
1970-01-01 08:00
China’s Junshi Nabs FDA Approval in Rare Success for US Foray
The US Food and Drug Administration has cleared the first China-developed cancer drug similar to Merck & Co.’s
1970-01-01 08:00
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
Merck & Co. won’t continue with two drug candidates it previously agreed to co-develop with a Chinese biotech
1970-01-01 08:00
China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US
As drugmakers in the US steel for price negotiations ushered in by President Joe Biden’s Inflation Reduction Act,
1970-01-01 08:00